Produktname:2-Chloro-6-methoxypurine

IUPAC Name:2-chloro-6-methoxy-7H-purine

CAS:1198-46-5
Molekulare Formel:C6H5ClN4O
Reinheit:95%+
Katalognummer:CM233995
Molekulargewicht:184.58

Packungseinheit Verfügbarer Vorrat Preis($) Menge
CM233995-1g in stock ǤǤŢ
CM233995-5g in stock NJʼnư

Nur für den Einsatz in Forschung und Entwicklung..

Anfrage-Formular

   refresh    

Produkt-Details

CAS-Nr.:1198-46-5
Molekulare Formel:C6H5ClN4O
Schmelzpunkt:-
SMILES-Code:COC1=C2NC=NC2=NC(Cl)=N1
Dichte:
Katalognummer:CM233995
Molekulargewicht:184.58
Siedepunkt:
Mdl-Nr.:MFCD20692004
Lagerung:Keep in inert atmosphere, store at 2-8°C.

Category Infos

Purines
Purines are heterocyclic aromatic compounds composed of linked pyrimidine and imidazole rings. In mammals, purines are most commonly expressed in DNA and RNA (including the purines adenine and guanine), as well as single-molecule nucleotides (adenosine triphosphate (ATP), adenosine diphosphate (ADP), adenosine monophosphate (AMP), cyclic AMP, and to a lesser extent guanosine triphosphate (GTP) and cyclic guanosine monophosphate (cGMP). Purines are also key elements of the following energy metabolism molecules: reduced nicotinamide adenine dinucleotide, nicotinamide adenine dinucleotide phosphate (NADPH), and coenzyme Q. Purines can also act as direct neurotransmitters; for example, adenosine may interact with receptors to modulate cardiovascular and central nervous system (CNS) function.
purine wholesale
Find trusted purine wholesaler. Any requirements and problems can ask us at any time.

Column Infos

Ibezapolstat
Acurx announces successful FDA end-of-phase 2 meeting and phase 3 readiness for Ibezapolstat in the treatment of C. difficile infection. The successful meeting outcomes include reaching key elements of Phase 3 clinical trial program and a development plan of NDA filling. C. difficile infection (CDI) is a bacterial infection of the colon, and causes diarrhea and colitis.
Ibezapolstat is a novel antibacterial agent that acts specially on DNA pol IIIC enzyme through competitive inhibition of dGTP (guanosine analog). Ibezapolstat has been granted Fast Track Designation from the U.S. FDA.